VERASTEM INC (VSTM) Stock News

NASDAQ:VSTM - US92337C2035 - Common Stock

9.255 USD

+0.01 (+0.05%)

Last: 9/2/2025, 3:54:05 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

VSTM Latest News, Press Relases and Analysis

All

Press Releases

20 days ago - By: Chartmill - Mentions: FOSL RRGB COHR CDXS ...

News Image

Curious about the stocks that are showing activity after the closing bell on Wednesday?

6 days ago - By: Verastem Oncology

Verastem Oncology to Present at Upcoming Investor Conferences

17 days ago - By: Yahoo Finance

Verastem Advances with Phase 3 Trial Progress and Product Launch Boosting Prospects

20 days ago - By: Benzinga - Mentions: CDXS PULM SNOA OVID ...

12 Health Care Stocks Moving In Wednesday's After-Market Session

20 days ago - By: Verastem Oncology

Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics’ Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung Cancer

26 days ago - By: Zacks Investment Research - Mentions: KMDA

Verastem (VSTM) Reports Q2 Loss, Misses Revenue Estimates

a month ago - By: Verastem Oncology

Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates

a month ago - By: Benzinga - Mentions: GSAT PGY ADV REAL ...

Earnings Scheduled For August 7, 2025

a month ago - By: Zacks Investment Research - Mentions: GOSS

Gossamer Bio (GOSS) Reports Q2 Loss, Beats Revenue Estimates

a month ago - By: Verastem Oncology

Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025

a month ago - By: Verastem Oncology

Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer

2 months ago - By: Verastem Oncology

Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology

2 months ago - By: FN Media Group LLC - Mentions: ONCY ONC.CA MBIO CRDF ...

Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies

2 months ago - By: Verastem Oncology

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: Verastem Oncology

Verastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Combination with Defactinib in Solid Tumors, including Low-Grade Serious Ovarian Cancer

2 months ago - By: Verastem Oncology

Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors

2 months ago - By: Zacks Investment Research - Mentions: EXAS GH TEM

Tempus AI's 89% Genomics Surge: Will the Momentum Keep Building?

3 months ago - By: Verastem Oncology

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor

3 months ago - By: Zacks Investment Research - Mentions: LXRX AMRN

VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval

3 months ago - By: Verastem Oncology

Verastem Oncology to Present at the Jefferies Global Healthcare Conference

3 months ago - By: Verastem Oncology

Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma

4 months ago - By: Yahoo Finance - Mentions: DB GOOG RBLX HD ...

Deutsche Bank Reaffirms Buy Rating on Roblox Amid Google Deal

4 months ago - By: Verastem Oncology

Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates

4 months ago - By: Verastem Oncology

FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer

4 months ago - By: Verastem Oncology

Verastem Oncology to Present at Upcoming Investor Conferences

4 months ago - By: Verastem Oncology

Verastem Oncology Announces $75 million Private Placement

4 months ago - By: Verastem Oncology

Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors